Novo Nordisk (NVO) revealed mixed third quarter results, the pharmaceutical giant narrowing its full-year sales growth guidance while posting a 79% year-over-year sales increase for its landmark weight-loss drug Wegovy.

Catalysts hosts Seana Smith and Madison Mills review Novo Nordisk's stock reaction to the earnings print, referencing CFO Karsten Munk Knudsen's comments to Yahoo Finance about the company's US and international sales growth for GLP-1 products.

To watch more expert insights and analysis on the latest market action, check out more Catalysts here.

This post was written by Luke Carberry Mogan.